I also do not have too much of a concern about the way the R&D is being capitalised as long as it is consistently reported each year.
In reality for the business though, GLH is going to have to continually keep investing in R&D to keep their existing customers, so some of the R&D is really more of an ongoing business expense. That is if they stopped the R&D altogether then at some point they would lose customers.
So ideally some portion of R&D should be expensed.
A potion of R&D that actually grows the business could be capitalised. But then that raises the question as to what percentage should be expensed / capitalised.
I feel that the figures in the accounts are clear enough the way they are and each investor should be able to make their own decision about the company performance from them.
The main thing is not to just look at a headline profit figure but perhaps more importantly consider the cashflow.
profit is an accounting construct and can be altered by accounting changes. It is possible for a company to go broke (run out of cash) while still reporting profits.
- Forums
- ASX - By Stock
- GLH
- forecast pe at 6
GLH
global health limited
Add to My Watchlist
1.49%
!
6.8¢

forecast pe at 6, page-33
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
6.8¢ |
Change
0.001(1.49%) |
Mkt cap ! $3.983M |
Open | High | Low | Value | Volume |
6.7¢ | 6.8¢ | 6.7¢ | $5.378K | 79.23K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 737 | 7.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.5¢ | 12750 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 737 | 0.072 |
1 | 4030 | 0.067 |
1 | 18500 | 0.051 |
1 | 5000 | 0.050 |
1 | 25000 | 0.040 |
Price($) | Vol. | No. |
---|---|---|
0.075 | 12750 | 1 |
0.135 | 4980 | 1 |
0.140 | 58909 | 1 |
0.155 | 30000 | 1 |
0.160 | 24240 | 1 |
Last trade - 13.01pm 03/07/2025 (20 minute delay) ? |
Featured News
GLH (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online